Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. saw a significant rise in stock performance on February 24, 2026, reaching an intraday high of USD 29.65. The company has shown resilience with a 41.95% increase over the past week, despite longer-term challenges and a market capitalization of USD 1,679 million.

Tandem Diabetes Care, Inc. has seen significant stock activity, achieving an intraday high and notable one-day performance. Despite recent gains and strong institutional backing, the company faces long-term challenges, including a decline in one-year performance and low profitability, as indicated by its return on equity.

Tandem Diabetes Care, Inc. has experienced significant stock price fluctuations, currently at $28.26. The company shows mixed technical indicators, with bullish trends in MACD and Bollinger Bands, while the RSI indicates bearishness. Despite a challenging year, recent performance suggests a potential shift in momentum compared to the S&P 500.

Tandem Diabetes Care, Inc. has seen notable stock activity today, contrasting with the modest performance of the S&P 500. While the company has gained significantly over the past week, its year-long performance reveals a substantial decline. The firm continues to face challenges with profitability and has a market capitalization of USD 845 million.

Tandem Diabetes Care, Inc. faced notable volatility on November 6, 2025, with a significant stock decline. Over the past week and month, the stock has continued to drop, reflecting a troubling long-term performance. Financial metrics reveal challenges, including low return on equity and high debt levels, indicating ongoing difficulties.

Tandem Diabetes Care, Inc. has experienced significant stock fluctuations, with a 52-week high of $42.70 and a low of $9.98. Recent evaluations show mixed technical indicators, and the company's performance has lagged behind the S&P 500, reflecting ongoing challenges in the market.

Tandem Diabetes Care, Inc. saw a notable increase in its stock price on October 3, 2025, reflecting strong short-term performance compared to the S&P 500. However, the company faces long-term challenges, including significant declines over the past year and five years, alongside concerns regarding its financial health.